Community First Bancshares Inc (NQ: CFBI )

7.298 USD UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Oct 20, 2020 Add to My Watchlist

Price and Volume

Volume	0
Open	7.298
Bid (Size)	0.0100 (1)
Ask (Size)	9.610 (6)
Prev. Close	7.298
Today's Range	7.298 - 7.298
52wk Range	5.360 - 12.05
Shares Outstanding	7,538,250
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020

October 13, 2020

Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020

Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis

October 06, 2020

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

Performance

YTD	-37.57%	-37.57%
1 Month	-6.10%	-6.10%
3 Month	+4.26%	+4.26%
6 Month	+1.93%	+1.93%
1 Year	-27.81%	-27.81%

More News

Can-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases Conference

September 30, 2020

Can-Fite to Participate in Two BioPharma Partnering Conferences

September 22, 2020

Community First Bancshares, Inc. Announces Adoption of Plan of Conversion for Second-Step Stock Offering

September 09, 2020

Can-Fite to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020

September 08, 2020

FDA Clears Can-Fite to Commence Phase II COVID-19 Study

August 31, 2020

Can-Fite Reports Second Quarter 2020 Financial Results & Provides Clinical Update

August 27, 2020

Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH

August 25, 2020

Can-Fite to Conduct Investor Call to Review Q2 Results and Provide Business Update on Thursday, August 27, 2020 at 4:15 p.m. ET

August 20, 2020

Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study

July 27, 2020

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.